Comments
Drug-maker Divis Laboratories is likely to post a net profit of around ₹420 crore in the second quarter ended September 30, 2023 as against ₹493 crore earned in the corresponding quarter of the last financial year.
The Hyderabad-based company will announce its second quarter numbers today.
- Also read: USFDA team visits Divi’s Lab facility
The likely decrease could be on account of the absence of an upside that the Hyderabad-based company had from Molnupiravir, a Covid19 drug, last year.
The analysts, however, forecast about three percent growth in the total revenue at ₹1,915 crore compared to ₹1,854 crore in the year-ago period.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.